Bimekizumab 3-year Maintenance of Response in Week 16 Responders with Moderate to Severe Plaque Psoriasis: Results from Five Phase 3/3b Trials

Main Article Content

Diamant Thaçi
April Armstrong
Kenneth B Gordon
Andrew Blauvelt
Carl Paul
Wolf-Henning Boehncke
Maggie Wang
Balint Szilagyi
Bengt Hoepken
Jeremy Lambert
Mark Lebwohl

Keywords

psoriasis

References

1. Adams R et al. Front Immunol 2020;11:1894

2. Reich K et al. Lancet 2021;397:487–98, NCT03370133

3. Gordon KB et al. Lancet 2021;397:475–86, NCT03410992

4. Warren RB et al. N Engl J Med 2021;385:130–41, NCT03412747

5. Reich K et al. N Engl J Med 2021;385:142–52, NCT03536884

6. Strober B et al. Br J Dermatol 2023;188:749–597, NCT03598790

7. Warren RB et al. J Invest Dermatol 2015;135:2632–40

8. Hongbo Y et al. J Invest Dermatol 2005;125:659–64

9. Bimzelx® (bimekizumab) Summary of Product Characteristics. 2023. Available at: https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf [Accessed September 2023].

Most read articles by the same author(s)

<< < 17 18 19 20 21 22